BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24679166)

  • 21. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
    Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients].
    Fendrich V; Habbe N; Celik I; Langer P; Zielke A; Bartsch DK; Rothmund M
    Dtsch Med Wochenschr; 2007 Feb; 132(5):195-200. PubMed ID: 17252361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors.
    Chi Y; Du F; Zhao H; Wang JW; Cai JQ
    World J Gastroenterol; 2014 Nov; 20(43):16252-7. PubMed ID: 25473180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems.
    Pomianowska E; Gladhaug IP; Grzyb K; Røsok BI; Edwin B; Bergestuen DS; Mathisen O
    Scand J Gastroenterol; 2010 Aug; 45(7-8):971-9. PubMed ID: 20441530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
    Sallinen V; Haglund C; Seppänen H
    Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
    Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E
    Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgery in malignant pancreatic neuroendocrine tumors.
    Nguyen SQ; Angel LP; Divino CM; Schluender S; Warner RR
    J Surg Oncol; 2007 Oct; 96(5):397-403. PubMed ID: 17469119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
    Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study.
    Le Roux C; Lombard-Bohas C; Delmas C; Dominguez-Tinajero S; Ruszniewski P; Samalin E; Raoul JL; Renard P; Baudin E; Robaskiewicz M; Mitry E; Cadiot G;
    Dig Liver Dis; 2011 Oct; 43(10):828-33. PubMed ID: 21641888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.
    Sigel CS; Guo H; Sigel KM; Zhang M; Rekhtman N; Lin O; Klimstra DS; Jungbluth AA; Tang LK
    Cancer Cytopathol; 2017 Mar; 125(3):188-196. PubMed ID: 28094897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
    Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
    JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary malignant pancreatic neoplasms in children and adolescents: a 20 year experience.
    Rojas Y; Warneke CL; Dhamne CA; Tsao K; Nuchtern JG; Lally KP; Vasudevan SA; Hayes-Jordan AA; Cass DL; Herzog CE; Hicks MJ; Kim ES; Austin MT
    J Pediatr Surg; 2012 Dec; 47(12):2199-204. PubMed ID: 23217876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
    Mirkin KA; Hollenbeak CS; Wong J
    J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.
    Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
    Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.